NEWS | Systemic stem cell therapy reduces malignant mesothelioma growth

NEWS | Systemic stem cell therapy reduces malignant mesothelioma growth

Systemic delivery of stem cells exprestune an apoptosis-inducing protein clever successfully incorposwift into malignant pleural mesothelioma (MPM) cells and subsequently induce their death, according to preclinical learn findings.

While further validation is necessityed, the research opens up the possibility of utune stem cell therapy to diminish tumour burden in this rare and bigly untreatable type of lung clevercer.

“Bone marrow-derived mesenchymal stem cells (MSCs) are appealing cleverdidates as vectors for anticlevercer therapies for a variety of reasons,” say Sam Janes (University College London, UK) and colleagues who performed the learn.

Indeed, in vitro studies have demonstraten that MSCs migswift towards tumour cells and in vivo studies that they clever then incorposwift into a variety of clevercer cell types. This is true in a variety of clevercer cell types, including lung metastases. MSCs clever also be delivered intravenously as well as intrapleurally.

“In this learn, we demonstrate for the first time that MSCs exprestune TRAIL (MSCTRAIL) induce apoptosis in MPM cells in vitro,” Janes and team report in Thorax. TRAIL, or tumour necrosis fbehaveor-related apoptosis-inducing ligand, is a transmembrane protein and an “exciting anticlevercer molecule”, the team explains.

Recombinant TRAIL has been tested in early clinical trials and demonstraten promitune results, but its short half-life of 32 minutes puposes that it would require multiple infusions to have any sustained therapeutic effect.

“MSCs house to and incorposwift into tumours in vivo when delivered via both intrapleural and intravenous routes,” the team notes, so utune these cells to deliver TRAIL is an interesting prospect for malignant mesothelioma, which is often too diffuse to surgically remove or does not respond well to chemotherapy.

The researchers used a variety of methods to demonstrate that MSCTRAIL could kill MPM cells in vitro and then house in on, and kill, tumour cells in animal model of malignant mesothelioma. Dual fluorescence and bioluminescent imaging were used to track the movement of the stem cells.

While both intrapleural and intravenous delivery of the stem cells was able to diminish the tumour burden in mice, intravenous administration seeped to have a greater effect. MSCTRAIL also resulted in a greater stage of cell death when compared with treatment with recombinant TRAIL in vitro.

“The therapeutic effect lookn with intravenous delivery could be related to greater engraftment of MSCs within the tumour and is an important finding when conmiddlering the future therapeutic role of MSCTRAIL therapy in the clinic,” the researchers conclude.


''Sharing Is Caring''

0 komentar